These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
56 related articles for article (PubMed ID: 11826460)
1. [Information to families with hereditary breast and ovarian cancer]. Levin T; Reichelt J; Heimdal K; Møller P Tidsskr Nor Laegeforen; 2001 Nov; 121(28):3292-4. PubMed ID: 11826460 [TBL] [Abstract][Full Text] [Related]
2. Prophylactic Oophorectomy: Reducing the U.S. Death Rate from Epithelial Ovarian Cancer. A Continuing Debate. Piver MS Oncologist; 1996; 1(5):326-330. PubMed ID: 10388011 [TBL] [Abstract][Full Text] [Related]
3. Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations. Casey MJ; Synder C; Bewtra C; Narod SA; Watson P; Lynch HT Gynecol Oncol; 2005 May; 97(2):457-67. PubMed ID: 15863145 [TBL] [Abstract][Full Text] [Related]
4. [Clinical and molecular diagnosis of inherited breast-ovarian cancer]. Chompret A J Gynecol Obstet Biol Reprod (Paris); 2003 Apr; 32(2):101-19. PubMed ID: 12717301 [TBL] [Abstract][Full Text] [Related]
5. [Inherited breast and ovarian cancers]. Gerdes AM; Ejlertsen B Ugeskr Laeger; 2006 Jun; 168(24):2367-9. PubMed ID: 16822422 [TBL] [Abstract][Full Text] [Related]
6. Mutational analysis of the BRCA1-interacting genes ZNF350/ZBRK1 and BRIP1/BACH1 among BRCA1 and BRCA2-negative probands from breast-ovarian cancer families and among early-onset breast cancer cases and reference individuals. Rutter JL; Smith AM; Dávila MR; Sigurdson AJ; Giusti RM; Pineda MA; Doody MM; Tucker MA; Greene MH; Zhang J; Struewing JP Hum Mutat; 2003 Aug; 22(2):121-8. PubMed ID: 12872252 [TBL] [Abstract][Full Text] [Related]
7. Molecular analysis of the BRCA1 and BRCA2 genes in 32 breast and/or ovarian cancer Spanish families. Osorio A; Barroso A; Martínez B; Cebrián A; San Román JM; Lobo F; Robledo M; Benítez J Br J Cancer; 2000 Apr; 82(7):1266-70. PubMed ID: 10755399 [TBL] [Abstract][Full Text] [Related]
8. Men at risk of being a mutation carrier for hereditary breast/ovarian cancer: an exploration of attitudes and psychological functioning during genetic testing. Lodder L; Frets PG; Trijsburg RW; Tibben A; Meijers-Heijboer EJ; Duivenvoorden HJ; Wagner A; van Der Meer CA; Devilee P; Cornelisse CJ; Niermeijer MF Eur J Hum Genet; 2001 Jul; 9(7):492-500. PubMed ID: 11464240 [TBL] [Abstract][Full Text] [Related]
9. Absence of genomic BRCA1 and BRCA2 rearrangements in Ashkenazi breast and ovarian cancer families. Stadler ZK; Saloustros E; Hansen NA; Schluger AE; Kauff ND; Offit K; Robson ME Breast Cancer Res Treat; 2010 Sep; 123(2):581-5. PubMed ID: 20221693 [TBL] [Abstract][Full Text] [Related]
10. Incidence of BRCA1 and BRCA2 mutations in 54 Chilean families with breast/ovarian cancer, genotype-phenotype correlations. Gallardo M; Silva A; Rubio L; Alvarez C; Torrealba C; Salinas M; Tapia T; Faundez P; Palma L; Riccio ME; Paredes H; Rodriguez M; Cruz A; Rousseau C; King MC; Camus M; Alvarez M; Carvallo P Breast Cancer Res Treat; 2006 Jan; 95(1):81-7. PubMed ID: 16261400 [TBL] [Abstract][Full Text] [Related]
11. Risk of ovarian cancer in BRCA1 and BRCA2 mutation-negative hereditary breast cancer families. Kauff ND; Mitra N; Robson ME; Hurley KE; Chuai S; Goldfrank D; Wadsworth E; Lee J; Cigler T; Borgen PI; Norton L; Barakat RR; Offit K J Natl Cancer Inst; 2005 Sep; 97(18):1382-4. PubMed ID: 16174860 [TBL] [Abstract][Full Text] [Related]
12. BRCA1 gene mutations may explain more than 80% of excess number of ovarian cancer cases after breast cancer - a population based study from the Western Sweden Health Care region. Einbeigi Z; Enerbäck C; Wallgren A; Nordling M; Karlsson P Acta Oncol; 2010 Apr; 49(3):361-7. PubMed ID: 20151938 [TBL] [Abstract][Full Text] [Related]
13. [The limited spectrum of pathogenic BRCA1 and BRCA2 mutations in the French Canadian breast and breast-ovarian cancer families, a founder population of Quebec, Canada]. Tonin PN Bull Cancer; 2006 Sep; 93(9):841-6. PubMed ID: 16980226 [TBL] [Abstract][Full Text] [Related]
15. Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada. Risch HA; McLaughlin JR; Cole DE; Rosen B; Bradley L; Fan I; Tang J; Li S; Zhang S; Shaw PA; Narod SA J Natl Cancer Inst; 2006 Dec; 98(23):1694-706. PubMed ID: 17148771 [TBL] [Abstract][Full Text] [Related]
16. Hereditary breast-ovarian cancer: clinical findings and medical management. Marshall M; Solomon S Plast Surg Nurs; 2007; 27(3):124-7. PubMed ID: 17901820 [TBL] [Abstract][Full Text] [Related]
17. Psychosocial issues following a positive result of genetic testing for BRCA1 and BRCA2 mutations: findings from a focus group and a needs-assessment survey. Di Prospero LS; Seminsky M; Honeyford J; Doan B; Franssen E; Meschino W; Chart P; Warner E CMAJ; 2001 Apr; 164(7):1005-9. PubMed ID: 11314429 [TBL] [Abstract][Full Text] [Related]
18. Differentiating pathogenic mutations from polymorphic alterations in the splice sites of BRCA1 and BRCA2. Claes K; Poppe B; Machackova E; Coene I; Foretova L; De Paepe A; Messiaen L Genes Chromosomes Cancer; 2003 Jul; 37(3):314-20. PubMed ID: 12759930 [TBL] [Abstract][Full Text] [Related]
19. G1738R is a BRCA1 founder mutation in Greek breast/ovarian cancer patients: evaluation of its pathogenicity and inferences on its genealogical history. Anagnostopoulos T; Pertesi M; Konstantopoulou I; Armaou S; Kamakari S; Nasioulas G; Athanasiou A; Dobrovic A; Young MA; Goldgar D; Fountzilas G; Yannoukakos D Breast Cancer Res Treat; 2008 Jul; 110(2):377-85. PubMed ID: 17902052 [TBL] [Abstract][Full Text] [Related]
20. BRCA1 and BRCA2 point mutations and large rearrangements in breast and ovarian cancer families in Northern Poland. Ratajska M; Brozek I; Senkus-Konefka E; Jassem J; Stepnowska M; Palomba G; Pisano M; Casula M; Palmieri G; Borg A; Limon J Oncol Rep; 2008 Jan; 19(1):263-8. PubMed ID: 18097605 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]